BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

Causeway Capital Commentary- Update on Covid019 Vaccines: A Major Breakthrough for mRNA Technology

Nearly four months ago I wrote that should the Covid-19 vaccine being developed by Pfizer Inc. (NYSE:PFE) prove successful, it could generate revenue of $15 billion. That expectation is moving closer to reality after the New York-based pharmaceutical leader and partner BioNTech SE (NASDAQ:BNTX) announced on Monday their leading candidate worked 90% of the time.

Sales of Pfizer's Covid Vaccine Could Hit $4.6 Billion in 2021

Johnson & Johnson and AstraZeneca pledged to make their vaccines available on a not-for-profit basis

Pfizer and BioNTech could make $13bn from coronavirus vaccine

Co-founded by Turkish scientists Uğur Şahin and his wife Özlem Türeci, BioNTech is now worth $25 billion.

Everything you need to know about BioNTech and the married couple behind the COVID-19 vaccine at the front of a global race

The German biotech thinks that its prospects are brighter than ever.

No Surprise Here: BioNTech's Q3 Results Driven by Its COVID-19 Vaccine Program

BioNTech on Tuesday signalled that order size would impact the per-dose price for its potential COVID-19 vaccine in the developed world.

BioNTech says vaccine pricing benchmark is for similar volumes

BioNTech (BNTX) miss estimates for earnings in the third quarter of 2020 while revenues beat the same.

BioNTech's (BNTX) Q3 Loss Wider-Than Expected, Revenues Beat

BioNTech , first in the race to produce evidence of a working COVID-19 vaccine, is planning to price the two-shot regimen below "typical market rates" and would differentiate pricing between countries or regions.

BioNTech to price vaccine below market rates, differentiate between regions

Pfizer's Covid-19 vaccine could grab $15 billion in profit from a $100 billion market -- if it can answer five big questions

Pfizer Covid-19 Vaccine's Five Big Unknowns

Shares of BioNTech (NASDAQ:BNTX) rose 7% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 586.67% year over year to ($1.03), which missed the estimate of ($0.42).

BioNTech: Q3 Earnings Insights

Conference call and webcast scheduled for November 10, 2020 at 8:00 a.m. ET (2:00 p.m. CET)

BioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress

Moderna

There are plenty of similarities between these two makers of coronavirus vaccine candidates, but the few differences make the choice clear.

Better Buy: Moderna vs. BioNTech

Boris Johnson said: “I just don't want to let people run away with the idea that this . . . is necessarily a home run, a slam dunk, a shot to the back of the net yet.

Pfizer vaccine is not a ‘slam dunk,' warns U.K. prime minister

A senior administration official said Monday that U.S. health officials are “extremely encouraged” by the announcement that Pfizer's coronavirus vaccine is highly effective in preventing Covid-19.

U.S. health officials 'very optimistic' Pfizer coronavirus vaccine and others 'could effectively end the pandemic'

Pfizer will likely have millions of coronavirus vaccine doses ready by the end of 2020 — and the company's CEO is willing to be one of the first to take it. The Manhattan-based drugmaker expects to churn out up to 50 million doses of the shot globally this year and is in “a very, very.

Pfizer CEO wants to be ‘among the first' to take COVID-19 vaccine

News that Pfizer Inc's experimental COVID-19 vaccine is more than 90% effective based on initial trial results renewed hope on Monday among world leaders, scientists and global investors that the battle against a pandemic that has killed over a million people could be won.

Pfizer COVID-19 vaccine news delivers hope around the globe

Bloomin' Brands

Dine Brands Global

Brinker International

Texas Roadhouse

News that Pfizer has an effective vaccine sent the sector surging.

Why Casual-Dining Stocks Are Soaring Today

This morning, we covered two pharmaceutical stocks that exploded after announcing some more-than-optimistic coronavirus vaccine news.

Options Traders Swarm PFE, BNTX After Vaccine News

Pfizer's encouraging news about the effectiveness of its Covid-19 vaccine came nearly a week after Election Day. But Pfizer CEO Albert Bourla says the timing had nothing to do with politics.

Pfizer CEO: Our vaccine timing had nothing to do with politics

Pfizer and BioNTech announced a 90% effective vaccine for COVID-19. Shares are soaring on the news, gaping up from pre-news $90 to current $101.66.

BioNTech COVID-19 Vaccine Sets Up >50% Annual Yield With 19% Downside Protection

Although the details of interim data from the Phase 3 trials of Pfizer Inc's (NYSE: PFE) COVID-19 vaccine study rea unclear, the results represent “a solid win” for the company, according to BofA Securities. The Pfizer Analyst: Geoff Meacham maintained a Neutral rating on Pfizer with an unchanged $39 price target.

Pfizer Analyst: Coronavirus Vaccine Moving Closer To Emergency Use Authorization

U.S. Health and Human Services Secretary Alex Azar said on Monday it would take several weeks for U.S. regulators to receive and then process data on Pfizer Inc's vaccine for the coronavirus before the government could potentially approve it.

Potential approval of Pfizer vaccine still several weeks away: U.S. official

Pfizer (PFE Quick QuotePFE - Free Report) may have discovered the COVID-19 vaccine that the world has been waiting for since this pandemic began. The equity markets are soaring this morning, being led by the cyclical underperformers, while 2020's parabolic tech stocks take a seat on the sidelines for once.

What A Vaccine Means For The Stock Market

"I had zero worry" going into the trial whether the vaccine was going to be safe, Isaacson told CNBC. But he does not know if he got the vaccine or the placebo.

Walter Isaacson, a participant in Pfizer's Covid vaccine trial, describes what it's like

AstraZeneca

Johnson & Johnson

Novavax

A safe and effective Covid-19 vaccine is seen by investors and policymakers as a solution to get the global economy back on track.

News for BioNTech SE Stock (BNTX)